



Original Article

Lipid-to-neutrophil ratios in predicting in-hospital outcomes in pulmonary thromboembolism

Neda Roshanravan^{1*}, Erfan Banisefid^{2*}, Samad Ghaffari¹, Sami Rassouli², Amirreza Naseri^{2,3,4}, Tohid Yahyapoor¹, Elnaz Javanshir^{1*}, Sina Hamzehzadeh^{2*}

¹Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

²Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran

³Research Center for Evidence Based-Medicine, Iranian EBM Center: A Joanna Briggs Institute Center of Excellence, Tabriz University of Medical Sciences, Tabriz, Iran

⁴Tabriz USERN Office, Universal Scientific Education and Research Network (USERN), Tabriz, Iran

Article info

Article History:

Received: July 15, 2024

Accepted: November 2, 2024

epublished: December 23, 2024

*Corresponding Authors:

Elnaz Javanshir,

Email: Elnaz.javanshir@yahoo.com;

Sina Hamzehzadeh,

Email: Hamzehzadehsina.shz@yahoo.com

*These authors contribute equally and both of them should be considered co-first authors.

Abstract

Introduction: Acute pulmonary thromboembolism (PTE) is one of the leading causes of death and severe disability. Considering the impact of inflammation and lipid profile on prevalence and prognosis of deep vein thrombosis and PTE, this study was conducted to assess the predictive value of lipid-to-neutrophil count ratios for the short-term survival of PTE patients.

Methods: This study is an analytical cross-sectional study. Data regarding the demographics, past medical history, vital signs, laboratory variables, and the outcomes of hospitalization were gathered from the Tabriz PTE registry. The receiver operating characteristics (ROC) curve and area under curve (AUC) were utilized for assessing the prognostic values. SPSS 26 was used for all of the statistical analysis.

Results: The population of this analytical cross-sectional study consists of 547 PTE patients of which 41 patients (7.5%) died during hospitalization. There was a significant difference between death and survived groups regarding cholesterol (146.00[60.50] vs. 165.50[59.75]; p -value<0.01), LDL (80.00[48.00] vs. 102.00[52.00]; p -value<0.01), HDL (31.00[19.00] vs. 35.00[14.00]; p -value=0.04). Cholesterol/neutrophil*1000 with a cut-off value of 22.014 (sensitivity: 56.7%; specificity: 61.3%), LDL/neutrophil*1000 with a cut-off value of 10.909 (sensitivity: 69.3%; specificity: 51.9%) and HDL/neutrophile *1000 with a cut-off value of 4.150 (sensitivity: 61.9%; specificity: 58.1%) can predict short-term survival in patients with acute PTE.

Conclusion: Based on our findings, patients with higher cholesterol/neutrophil, LDL/neutrophil, and HDL/neutrophil ratios have a better in-hospital prognosis and measurement of lipid-to-neutrophil ratio in the first 24 hours of hospitalization may be a valuable marker for determining the early prognosis of PTE. However, additional clinical studies are suggested for a more definitive conclusion.

Keywords: Mortality, Neutrophil to high-density lipoprotein, Pulmonary thromboembolism, Prognosis

Introduction

Pulmonary thromboembolism (PTE) is the third most common cause of cardiovascular mortality worldwide after stroke and myocardial infarction (MI).¹ The annual incidence of PTE is approximately 300 000 to 600 000 cases in the United States (US) and Europe² and it is increasing over the past 20 years.³ PTE imposes a significant economic burden on the healthcare system.⁴

Risk stratification plays an important role in patients with acute PTE. Thrombolytic therapy or surgical embolectomy should be considered in patients with high-risk PTE.⁵ There are many clinical risk scores for evaluating PTE prognosis. The most common one is the Pulmonary Embolism Severity Index (PESI)⁶; beyond

that, the availability of some blood parameters can also help us determine the PTE prognosis.^{7,8}

Neutrophils are one of the major components of leukocytes in the peripheral blood and play a significant role in thrombosis. It can be determined in a cheap and easily available way. Recent studies showed an increase in the blood level of neutrophils in patients with PTE.^{9,10} Also, total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and triglyceride (TG) are found to be associated with the incidence and prognosis of venous thromboembolism (VTE) and PTE.^{11,12} Based on pioneering investigations high serum HDL and TC levels are could be associated with a decreased risk of deep vein thrombosis (DVT). Studies also claim that high TG



levels are associated with increased risk of DVT.¹³ HDL is also shown to have a negatively correlation with the onset of PTE.¹⁴ In addition, dyslipidemia is suggested to be correlated with PTE mortality. Higher initial serum HDL, LDL, and TC levels were reported to be associated with lower mortality rates in PTE patients.¹⁵

Best of our knowledge, there is no study on the association between lipid-to-neutrophil ratios and the mortality of acute PTE. With these considerations, our study was conducted to assess the predictive value of lipid-to-neutrophil ratios for in-hospital mortality (IHM) in patients with acute PTE.

Materials and Methods

This study is an analytical cross-sectional study that was conducted between April 2019 and September 2022 at Shahid Madani Medical and Training Heart Hospital, affiliated with Tabriz University of Medical Sciences (TUOMS). The study process was reviewed and approved by the ethics committee of TUOMS, according to the declaration of Helsinki.

The data for this research was retrieved from the Tabriz PTE registry. Informed consent was obtained from all subjects and/ or their legal guardian(s) who have participated in our study. Inclusion criteria were hospitalization with confirmed acute PTE diagnosis based on computed tomography (CT) pulmonary angiography by two expert radiologists, age ≥ 18 , and availability of complete blood count data (CBC with *differential* measures of the number of each type of white blood cells). The exclusion criteria were chronic PTE. IHM was defined as any mortality during hospitalization due to PTE. Therefore, patients with mortality due to other causes were excluded from our sample. Information regarding the demographic characteristics, past medical history, vital signs (taken in the emergency unit), laboratory variables based on first fasting results after administration, and outcomes of hospitalization were collected and investigated ratios were calculated by dividing the lipid levels by the neutrophil counts. For example, cholesterol/neutrophil*1000 was calculated by dividing the serum TC levels (in mg/dL) by serum neutrophil counts per microliter multiplied in 1000.

Statistical analysis

The twenty-sixth version of SPSS Statistics was utilized for statistical analysis. The normality of the destitution of the numeric variables was assessed using the Kolmogorov–Smirnov test. Categorical variables are presented in number and percent. The Chi-square test was utilized for comparing these variables. Numerical parameters are reported in mean $\pm$ standard deviation (SD) or median and interquartile range (IQR), based on normality. The comparison between these variables was conducted using the independent sample t-test or Mann-Whitney U test. In addition, multivariate logistic regression analysis was

conducted. Finally, the receiver operating characteristics (ROC) curve and area under curve (AUC) were utilized for the prediction of the IHM. In all applied statistics, 95% confidence intervals and a 0.05 level of significance for p-value were observed.

Results

Totally, 547 patients, including 253 males (46.2%) and 294 females (53.8%) included in this study. In [Table 1](#) demographic characteristics and laboratory findings of patients who died due to PTE are compared to patients

Table 1. The comparison of characteristics of the patients

Characteristics	Death (n=41)	Alive (n=506)	P value
Age	77.00 [20.00]	71.00 [28.00]	0.07
Sex (male: female)	20 (48.8%): 21 (51.2%)	233 (46.0%): 273 (54.0%)	0.52
peak CTNI	0.10 [0.17]	0.10 [0.10]	0.16
D-dimer	3.45 [505.93]	2.30 [11.63]	0.97
BUN	27.00 [32.50]	20.00 [13.00]	<0.01*
Creatinine	1.25 [0.70]	1.10 [0.40]	<0.01*
Blood sugar	116.00 [58.00]	116.00 [58.00]	0.56
Hb	12.97 $\pm$ 3.08	13.23 $\pm$ 2.26	0.40
HCT	40.40 [12.60]	40.63 [8.40]	0.84
MCV	88.00 [7.70]	86.00 [8.10]	0.08
RDW	50.05 [10.2]	46.90 [6.70]	<0.01*
WBC*1000	11.00 [7.30]	9.90 [4.90]	0.32
Neutrophil*1000	7.80 [6.79]	6.95 [4.33]	0.50
Lymphocyte*1000	1.35 [1.06]	1.70 [1.27]	<0.01*
PLT*1000	175.00 [149.00]	197.00 [97.25]	0.04*
MPV	10.00 [1.90]	9.80 [1.30]	0.16
SBP	110.00 [30.00]	120.00 [30.00]	<0.01*
HR	98.00 [26.50]	99.00 [30.00]	0.99
RR	20.00 [6.00]	20.00 [6.00]	0.44
BT	37.00 [0.30]	37.00 [0.30]	0.71
TG	113.00 [72.50]	117.00 [71.00]	0.46
Cholesterol	146.00 [60.50]	165.50 [59.75]	<0.01*
LDL	80.00 [48.00]	102.00 [52.00]	<0.01*
HDL	31.00 [19.00]	35.00 [14.00]	0.04*
HTN	25 (61.0%)	201 (39.7%)	<0.01*
DM	12 (29.3%)	90 (17.8%)	0.06
Smoking	8 (19.5%)	65 (12.8%)	0.22
Ratios			
Cholesterol/Neutrophile*1000	17.75 [15.24]	23.51 [17.45]	<0.01*
LDL/Neutrophile*1000	9.47 [9.74]	14.60 [13.42]	<0.01*
HDL/Neutrophile*1000	3.37 [3.36]	4.97 [3.81]	<0.01*

The numeric data are presented in median [IQR] or mean $\pm$ SD, based on the normality of distributions and nominal data are presented in number (percentage).

CTNI: Cardiac Troponin I; BUN: Blood urea nitrogen; Hb: Hemoglobin; HCT: Hematocrit; MCV: Mean corpuscular volume; RDW: Red cell distribution width; WBC: White blood cells; PLT: Platelets; MPV: Mean platelet volume; SBP: Systolic blood pressure; HR: Heart rate; RR: Respiratory rate; BT: Body temperature; TG: Triglycerides; LDL: Low-density lipoprotein; HDL: High-density lipoprotein; HTN: Hypertension; DM: Diabetes mellitus.

who survived it. There was a significant difference between death and survived groups regarding blood urea nitrogen (BUN) (P value < 0.01), creatinine (P value < 0.01), red cell distribution width (RDW) (P value < 0.01), lymphocyte (P value < 0.01), platelet (PLT) (P value = 0.04), systolic blood pressure (SBP) (P value < 0.01), cholesterol (P value < 0.01), LDL (P value < 0.01), HDL (P value = 0.04), and HTN (P value < 0.01). In Table 2 results of logistic regression analysis for factors associated with PTE and IHM are shown. This analysis showed that none of these factors independently play a role in PTE and IHM association.

Based on our findings, cholesterol/neutrophil*1000 with a cut-off value of 22.014 can predict short-term survival in PTE patients with 56.7% sensitivity and 61.3% specificity (AUC: 0.71 [95%CI: 0.62-0.80], P value < 0.01). Also, LDL/neutrophil*1000 with a cut-off value of 10.909 (sensitivity: 69.3%; specificity: 51.9%; AUC: 0.72 [95%CI: 0.63-0.81], P value < 0.01) and HDL/neutrophil*1000 with a cut-off value of 4.150 (sensitivity: 61.9%; specificity: 58.1%; AUC: 0.59 [95%CI: 0.52-0.67], P value < 0.01) can predict short-term survival in patients with acute PTE, too. Between the mentioned parameters, LDL/neutrophil, cholesterol/neutrophil, and HDL/neutrophil were found to be the best prognostic factors for the short-term survival of patients with PTE. ROC curves for each of the discussed ratios are presented in Figure 1.

Table 2. Factors associated with in-hospital mortality in multivariate logistic regression analysis

Characteristics	B (95%CI)	P value
SBP	1.011 (0.994 – 1.029)	0.207
HTN	2.093 (0.865 – 5.067)	0.101
DM	1.080 (0.402 – 2.901)	0.879
TG	1.000 (0.995 – 1.004)	0.973
Cholesterol	1.010 (0.972 – 1.049)	0.624
LDL	1.012 (0.964 – 1.062)	0.641
HDL	0.962 (0.889 – 1.041)	0.340
Hb	0.951 (0.791 – 1.142)	0.589
RDW	0.999 (0.979 – 1.020)	0.937
Neutrophil*1000	1.000 (1.000 – 1.000)	0.715
Lymphocyte*1000	1.000 (1.000 – 1.001)	0.102
PLT*1000	1.000 (1.000 – 1.000)	0.399
peak CTNI	1.181 (0.634 – 2.199)	0.601
BUN	0.979 (0.952 – 1.007)	0.143
Creatinine	0.866 (0.579 – 1.294)	0.482
Cholesterol/Neutrophile	1.013 (0.766 – 1.339)	0.930
LDL/Neutrophile	0.902 (0.639 – 1.274)	0.559
HDL/Neutrophile	1.382 (0.808 – 2.362)	0.238

CTNI: Cardiac Troponin I; Hb: Hemoglobin; RDW: Red cell distribution width; SBP: Systolic blood pressure; HR: Heart rate; RR: Respiratory rate; BT: Body temperature; TG: Triglycerides; LDL: Low-density lipoprotein; HDL: High-density lipoprotein; HTN: Hypertension; DM: Diabetes mellitus; PLT: Platelets; BUN: Blood urea nitrogen.

Discussion

This study was designed to assess the predictive value of lipid-to-neutrophil ratios for the short-term survival of patients with PTE. We concluded that cholesterol/neutrophil, LDL/neutrophil, and HDL/neutrophil ratios have a moderate predictive power in the short-term prognosis of patients with PTE. However, this correlation lost its significance in multivariate logistic regression. This could be due to the presence of interaction with other indicators or the presence of many predictor variables, assuming a suitable sample size and sufficient power.

PTE has an incidence rate of approximately 60-70 per 100 000, among the general population and if untreated, its mortality can be as high as 30%.¹⁶⁻¹⁸ Because most PTE patients ultimately die within the first hours of presentation, early diagnosis and having an insight into its possible prognosis are of paramount importance.¹⁹ Few scores are used to determine the prognosis of PTE patients like PESI and simplified PESI score, Geneva score, and 2014 European Society of Cardiology (ESC) mode, however recent studies indicate that the Geneva risk score and 2014 ESC model are not reliable to identify the high-risk PTE patients. Moreover, although the PESI score can be reliable for identifying the low risk of early mortality in PTE patients, clinicians still question its ability to identify the high risk of early mortality in them.²⁰⁻²² Recent studies have indicated several laboratory parameters including brain natriuretic peptide (BNP), N-terminal-proB-type Natriuretic Peptide (NT-proBNP), interleukin (IL)-6, IL-8, heart-type fatty acid binding protein (H-FABP), troponin and myoglobin as a possible prognostic factor for PTE patients,^{17,18} however, accessibility, availability, and cost-effectiveness limit their use in the clinical practice. In this condition, the widely available and accessible parameters such as CBC, diff findings and lipid profile are suggested as an appropriate predictive factor for mortality in PTE patients. Studies have reported ratios like monocytes to HDL ratio or neutrophil to lymphocyte ratio as probable prognostic factors for PTE.^{23,24} This study found cholesterol/neutrophil, LDL/neutrophil, and HDL/neutrophil ratios as possible predictive factors for IHM in PTE patients.

Recently, a new concept called “lipid paradox” has been introduced which means that a lower rate of lipid parameters like serum TC, LDL, and TG have a significant relationship with a higher rate of IHM in cardiovascular diseases like acute coronary syndrome and myocardial infarction.²⁵ From the pathophysiological point of view, the basis of the thrombotic process is inflammation leading to oxidative changes that can decrease cholesterol synthesis. Also, acute-phase reactants can increase cholesterol uptake by hepatocytes.^{26,27} In addition, recent studies on mice have shown that HDL and Cholesterol have an important role in lung normal function and have a vital role in the regulation of pulmonary inflammatory response after tissue injury.^{28,29} Studies also demonstrate




Figure 1. The ROC curves for predicting short-term survival for the variables investigated in this study. LDL: Low-density lipoprotein; HDL: High-density lipoprotein

a correlation between venous Thromboembolism (VTE) and inflammation.³⁰ On the other hand, HDL can protect endothelial cells against inflammation and oxidative stress by preventing monocyte flow to the arterial wall, which reduces the expression of CD11b on monocyte and endothelial molecules and prevents the adhesion of monocytes to the endothelial wall.³¹⁻³³ Finally, TGs are known as important energy sources for peripheral organs. An increase in acute phase reactions increases the function of lipoprotein lipase that breaks down circulating TGs and results in lower TG levels.³⁴ In a study by Karatas et al serum TC, LDL, HDL, and TG levels were significantly lower in deceased patients when compared to the surviving PTE patients.¹² In another study by Avci et al, serum levels of HDL were also significantly lower in deceased PTE patients.²³ In this study also the serum TC, LDL, HDL, and TG levels were significantly lower in PTE patients who died during their hospitalization.

On the other hand, studies indicate that leukocyte count could be related to fibrinogen, factor VII, and factor VIII levels and can cause local thrombogenic activity.^{35,36} Moreover, stimulated neutrophils may be responsible for vascular injury due to increased cytokines secretion³⁷, which can be a result of severe hypoxia caused by pulmonary artery obstruction and an increase in neuro-hormone and adrenergic system activity. This reaction may aggravate thrombosis and the severity of the disease in patients.³⁸ In a study by Kayrak et al WBC, neutrophil, and lymphocyte counts were significantly higher in deceased PTE patients in comparison to survivors.³⁹ Another study by ÇAVUŞ et al also indicates the same result.²⁴ In this study, lymphocyte count was significantly higher in the mortality group however WBC and neutrophil count didn't have a significant difference between the death and alive groups.

Recent investigations suggested the neutrophil to HDL ratio as a prognostic factor for the severity of coronary arteries stenosis,⁴⁰ clinical outcomes of patients with MI⁴¹, and all-cause and cardiovascular mortality in the general population.⁴² As one of the first tries, we investigated the relationship between lipids to neutrophil ratios and IHM of PTE patients in a great cohort and we found cholesterol/neutrophil, HDL/neutrophil, and LDL/neutrophil ratios as good predictors of short-term survival in PTE patients. Some limitations may affect our findings. One of them is the retrospective design of the study and the second one is the lack of long-term follow-up in the study. Also, this study was not able to exclude patients who had a drug history of statins. Furthermore, it's recommended to compare the suggested ratios in this study with other risk scores such as PESI in future studies. Considering the impacts of acute PTE-related inflammation on lipid profile,^{43,44} this study cannot ensure that measured lipid levels and calculated ratio represent patients' chronic lipid status. In addition, this study suggests larger prospective multicenter studies to evaluate the possible role of serum lipid profile and cholesterol/neutrophil ratio in the prognosis of PTE, while considering the possible confounders such as body mass index (BMI) and recent weight loss. In case of approval of the findings of this investigation in future studies, we suggest that the mentioned ratio could be included in the risk stratification algorithms of PTE.

Conclusion

PTE patients with $\text{cholesterol/neutrophil} \times 1000 < 22.014$, $\text{LDL/neutrophil} \times 1000 < 10.909$, and $\text{HDL/neutrophil} \times 1000 < 4.150$ have a higher rate of IHM, which suggests these ratios are a good prognostic factor for predicting short-term mortality in PTE patients. Measurement of lipid to neutrophil in the first 24 hours of hospitalization may be

a valuable marker for determining the early prognosis of PTE.

Acknowledgments

The research protocol was approved and supported by the Student Research Committee, Tabriz University of Medical Sciences (grant number: 70814). The authors also would like to appreciate the cooperation of the clinical research development unit of Shahid Madani Hospital, Tabriz, Iran.

Authors' Contribution

Conceptualization: Neda Roshanravan, Samad Ghaffari, Elnaz Javanshir.

Formal analysis: Amirreza Naseri, Erfan Banisefid, Sina Hamzehzadeh.

Funding acquisition: Amirreza Naseri, Erfan Banisefid, Sami Rassouli, Neda Roshanravan, Samad Ghaffari, Elnaz Javanshir, Sina Hamzehzadeh.

Investigation: Neda Roshanravan, Samad Ghaffari, Elnaz Javanshir, Erfan Banisefid, Sami Rassouli, Tohid Yahyapoor.

Methodology: Neda Roshanravan, Samad Ghaffari, Elnaz Javanshir, Amirreza Naseri, Erfan Banisefid.

Project administration: Amirreza Naseri, Erfan Banisefid, Sami Rassouli, Neda Roshanravan, Samad Ghaffari, Elnaz Javanshir, Sina Hamzehzadeh.

Resources: Neda Roshanravan, Samad Ghaffari, Elnaz Javanshir.

Supervision: Neda Roshanravan, Samad Ghaffari, Elnaz Javanshir.

Validation: Neda Roshanravan, Samad Ghaffari, Elnaz Javanshir.

Visualization: Amirreza Naseri, Erfan Banisefid, Sami Rassouli.

Writing-original draft: Amirreza Naseri, Erfan Banisefid, Sami Rassouli, Tohid Yahyapoor, Sina Hamzehzadeh.

Writing-review & editing: Neda Roshanravan, Samad Ghaffari, Elnaz Javanshir.

Competing Interests

None.

Ethical Approval

The study process was reviewed and approved by the ethics committee of Tabriz University of Medical Sciences, according to the declaration of Helsinki (ethics code: IR.TBZMED.REC.1401.1011).

Funding

This work was supported by Deputy for Research of Tabriz University of Medical Sciences.

References

- Essien EO, Rali P, Mathai SC. Pulmonary embolism. *Med Clin North Am*. 2019;103(3):549-64. doi: [10.1016/j.mcna.2018.12.013](#).
- Cohen AT, Agnelli G, Anderson FA, Arcelus JJ, Bergqvist D, Brecht JG, et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. *Thromb Haemost*. 2007;98(4):756-64. doi: [10.1160/th07-03-0212](#).
- Barco S, Valerio L, Gallo A, Turatti G, Mahmoudpour SH, Ageno W, et al. Global reporting of pulmonary embolism-related deaths in the World Health Organization mortality database: vital registration data from 123 countries. *Res Pract Thromb Haemost*. 2021;5(5):e12520. doi: [10.1002/rth2.12520](#).
- Grosse SD, Nelson RE, Nyarko KA, Richardson LC, Raskob GE. The economic burden of incident venous thromboembolism in the United States: a review of estimated attributable healthcare costs. *Thromb Res*. 2016;137:3-10. doi: [10.1016/j.thromres.2015.11.033](#).
- Yamamoto T. Management of patients with high-risk pulmonary embolism: a narrative review. *J Intensive Care*. 2018;6:16. doi: [10.1186/s40560-018-0286-8](#).
- Howard L. Acute pulmonary embolism. *Clin Med (Lond)*. 2019;19(3):243-7. doi: [10.7861/clinmedicine.19-3-247](#).
- Ghaffari S, Parvizian N, Pourafkari L, Separham A, Hajizadeh R, Nader ND, et al. Prognostic value of platelet indices in patients with acute pulmonary thromboembolism. *J Cardiovasc Thorac Res*. 2020;12(1):56-62. doi: [10.34172/jcvtr.2020.09](#).
- Kaur S, Manje Gowda A, Kumar A, Ishfaq A, Bansal R, Agrawal A, et al. Role of hematological parameters in predicting severity of acute venous thromboembolism. *Blood*. 2017;130:4903. doi: [10.1182/blood.V130.Suppl_1.4903.4903](#).
- Shan T, Li X, Yan M, Pan X. Evaluation of prognosis and risk of death by neutrophil/lymphocyte ratio, C-reactive protein/albumin ratio and plasma D-dimer in patients with pulmonary thromboembolism. *Int J Gen Med*. 2021;14:9219-25. doi: [10.2147/ijgm.S343039](#).
- Kapoor S, Opneja A, Nayak L. The role of neutrophils in thrombosis. *Thromb Res*. 2018;170:87-96. doi: [10.1016/j.thromres.2018.08.005](#).
- Eichinger S, Pecheniuk NM, Hron G, Deguchi H, Schemper M, Kyrle PA, et al. High-density lipoprotein and the risk of recurrent venous thromboembolism. *Circulation*. 2007;115(12):1609-14. doi: [10.1161/circulationaha.106.649954](#).
- Karataş MB, Güngör B, İpek G, Çanga Y, Günaydın ZY, Onuk T, et al. Association of serum cholesterol levels with short-term mortality in patients with acute pulmonary embolism. *Heart Lung Circ*. 2016;25(4):365-70. doi: [10.1016/j.hlc.2015.09.005](#).
- Huang Y, Ge H, Wang X, Zhang X. Association between blood lipid levels and lower extremity deep venous thrombosis: a population-based cohort study. *Clin Appl Thromb Hemost*. 2022;28:10760296221121282. doi: [10.1177/10760296221121282](#).
- Wang Y, Wang P, Li H. Correlation study of pulmonary embolism and high-density lipoprotein cholesterol. *Clin Cardiol*. 2010;33(2):72-6. doi: [10.1002/clc.20692](#).
- Roshanravan N, Seyed Ghiasi N, Ghaffari S, Ghasemnezhad Saadatlou S, Seifimansour S, Hamzehzadeh S, et al. Lipid profile and mortality in patients with pulmonary thromboembolism; a systematic review and meta-analysis. *J Basic Clin Physiol Pharmacol*. 2024;35(4-5):205-12. doi: [10.1515/jbcpp-2024-0085](#).
- Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale. *Thromb Haemost*. 2000;83(5):657-60.
- Torbicki A, Perrier A, Konstantinides S, Agnelli G, Galiè N, Pruszczyk P, et al. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). *Eur Heart J*. 2008;29(18):2276-315. doi: [10.1093/eurheartj/ehn310](#).
- GoldhaberSZ, Visani L, DeRosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). *Lancet*. 1999;353(9162):1386-9. doi: [10.1016/s0140-6736\(98\)07534-5](#).
- Bélohlávek J, Dytrych V, Linhart A. Pulmonary embolism, part I: epidemiology, risk factors and risk stratification, pathophysiology, clinical presentation, diagnosis and nonthrombotic pulmonary embolism. *Exp Clin Cardiol*. 2013;18(2):129-38.
- Natanzon SS, Fardman A, Chernomordik F, Mazin I, Herscovici R, Goitein O, et al. PESI score for predicting clinical

- outcomes in PE patients with right ventricular involvement. *Heart Vessels*. 2022;37(3):489-95. doi: [10.1007/s00380-021-01924-w](https://doi.org/10.1007/s00380-021-01924-w).
21. Jiménez D, Yusen RD. Prognostic models for selecting patients with acute pulmonary embolism for initial outpatient therapy. *Curr Opin Pulm Med*. 2008;14(5):414-21. doi: [10.1097/MCP.0b013e3283043e44](https://doi.org/10.1097/MCP.0b013e3283043e44).
 22. Masotti L, Panigada G, Landini G, Pieralli F, Corradi F, Lenti S, et al. Predictive ability of the new 2014 ESC prognostic model in acute pulmonary embolism. *Int J Cardiol*. 2016;202:801-3. doi: [10.1016/j.ijcard.2015.10.007](https://doi.org/10.1016/j.ijcard.2015.10.007).
 23. Avci A, Biricik S, Avci BS, Yesiloglu O, Sumbul HE, Icme F, et al. The new prognostic factor for pulmonary embolism: the ratio of monocyte count to HDL cholesterol. *Am J Emerg Med*. 2021;46:212-6. doi: [10.1016/j.ajem.2020.07.026](https://doi.org/10.1016/j.ajem.2020.07.026).
 24. Cavaş UY, Yildirim S, Sönmez E, Ertan C, Ozeke O. Prognostic value of neutrophil/lymphocyte ratio in patients with pulmonary embolism. *Turk J Med Sci*. 2014;44(1):50-5.
 25. Cheng KH, Chu CS, Lin TH, Lee KT, Sheu SH, Lai WT. Lipid paradox in acute myocardial infarction-the association with 30-day in-hospital mortality. *Crit Care Med*. 2015;43(6):1255-64. doi: [10.1097/ccm.0000000000000946](https://doi.org/10.1097/ccm.0000000000000946).
 26. Zarezadeh M, Musazadeh V, Faghfour AH, Roshanravan N, Dehghan P. Probiotics act as a potent intervention in improving lipid profile: an umbrella systematic review and meta-analysis. *Crit Rev Food Sci Nutr*. 2023;63(2):145-58. doi: [10.1080/10408398.2021.2004578](https://doi.org/10.1080/10408398.2021.2004578).
 27. Wang X, Liao D, Bharadwaj U, Li M, Yao Q, Chen C. C-reactive protein inhibits cholesterol efflux from human macrophage-derived foam cells. *Arterioscler Thromb Vasc Biol*. 2008;28(3):519-26. doi: [10.1161/atvbaha.107.159467](https://doi.org/10.1161/atvbaha.107.159467).
 28. McCrae KC, Weltman B, Alyward S, Shaw RA, Sowa MG, Unruh HW, et al. The effect of elevated dietary cholesterol on pulmonary surfactant function in adolescent mice. *Pediatr Pulmonol*. 2008;43(5):426-34. doi: [10.1002/ppul.20772](https://doi.org/10.1002/ppul.20772).
 29. Vockeroth D, Gunasekara L, Amrein M, Possmayer F, Lewis JF, Veldhuizen RA. Role of cholesterol in the biophysical dysfunction of surfactant in ventilator-induced lung injury. *Am J Physiol Lung Cell Mol Physiol*. 2010;298(1):L117-25. doi: [10.1152/ajplung.00218.2009](https://doi.org/10.1152/ajplung.00218.2009).
 30. Branchford BR, Carpenter SL. The role of inflammation in venous thromboembolism. *Front Pediatr*. 2018;6:142. doi: [10.3389/fped.2018.00142](https://doi.org/10.3389/fped.2018.00142).
 31. Kundi H, Gok M, Kiziltunc E, Cetin M, Cicekcioglu H, Cetin ZG, et al. Relation between monocyte to high-density lipoprotein cholesterol ratio with presence and severity of isolated coronary artery ectasia. *Am J Cardiol*. 2015;116(11):1685-9. doi: [10.1016/j.amjcard.2015.08.036](https://doi.org/10.1016/j.amjcard.2015.08.036).
 32. Kadihasanoglu M, Karabay E, Yucetas U, Erkan E, Ozbek E. Relation between monocyte to high-density lipoprotein cholesterol ratio and presence and severity of erectile dysfunction. *Aktuelle Urol*. 2018;49(3):256-61. doi: [10.1055/s-0042-123163](https://doi.org/10.1055/s-0042-123163).
 33. Murphy AJ, Woollard KJ, Hoang A, Mukhamedova N, Stirzaker RA, McCormick SP, et al. High-density lipoprotein reduces the human monocyte inflammatory response. *Arterioscler Thromb Vasc Biol*. 2008;28(11):2071-7. doi: [10.1161/atvbaha.108.168690](https://doi.org/10.1161/atvbaha.108.168690).
 34. Klingenspor M, Ebbinghaus C, Hülshorst G, Stöhr S, Spiegelhalter F, Haas K, et al. Multiple regulatory steps are involved in the control of lipoprotein lipase activity in brown adipose tissue. *J Lipid Res*. 1996;37(8):1685-95.
 35. Bovill EG, Bild DE, Heiss G, Kuller LH, Lee MH, Rock R, et al. White blood cell counts in persons aged 65 years or more from the Cardiovascular Health Study. Correlations with baseline clinical and demographic characteristics. *Am J Epidemiol*. 1996;143(11):1107-15. doi: [10.1093/oxfordjournals.aje.a008687](https://doi.org/10.1093/oxfordjournals.aje.a008687).
 36. Zarbock A, Polanowska-Grabowska RK, Ley K. Platelet-neutrophil-interactions: linking hemostasis and inflammation. *Blood Rev*. 2007;21(2):99-111. doi: [10.1016/j.blre.2006.06.001](https://doi.org/10.1016/j.blre.2006.06.001).
 37. Li DB, Hua Q, Liu Z, Li J, Xu LQ, Wang S, et al. Association between inflammatory mediators and angiographic morphologic features indicating thrombus formation in patients with acute myocardial infarction. *Chin Med J (Engl)*. 2009;122(15):1738-42.
 38. Zorlu A, Bektasoglu G, Guven FM, Dogan OT, Gucuk E, Ege MR, et al. Usefulness of admission red cell distribution width as a predictor of early mortality in patients with acute pulmonary embolism. *Am J Cardiol*. 2012;109(1):128-34. doi: [10.1016/j.amjcard.2011.08.015](https://doi.org/10.1016/j.amjcard.2011.08.015).
 39. Kayrak M, Erdogan HI, Solak Y, Akilli H, Gül EE, Yildirim O, et al. Prognostic value of neutrophil to lymphocyte ratio in patients with acute pulmonary embolism: a retrospective study. *Heart Lung Circ*. 2014;23(1):56-62. doi: [10.1016/j.hlc.2013.06.004](https://doi.org/10.1016/j.hlc.2013.06.004).
 40. Kou T, Luo H, Yin L. Relationship between neutrophils to HDL-C ratio and severity of coronary stenosis. *BMC Cardiovasc Disord*. 2021;21(1):127. doi: [10.1186/s12872-020-01771-z](https://doi.org/10.1186/s12872-020-01771-z).
 41. Huang JB, Chen YS, Ji HY, Xie WM, Jiang J, Ran LS, et al. Neutrophil to high-density lipoprotein ratio has a superior prognostic value in elderly patients with acute myocardial infarction: a comparison study. *Lipids Health Dis*. 2020;19(1):59. doi: [10.1186/s12944-020-01238-2](https://doi.org/10.1186/s12944-020-01238-2).
 42. Jiang M, Sun J, Zou H, Li M, Su Z, Sun W, et al. Prognostic role of neutrophil to high-density lipoprotein cholesterol ratio for all-cause and cardiovascular mortality in the general population. *Front Cardiovasc Med*. 2022;9:807339. doi: [10.3389/fcvm.2022.807339](https://doi.org/10.3389/fcvm.2022.807339).
 43. Nikpayam O, Najafi M, Ghaffari S, Asghari Jafarabadi M, Sohrab G, Roshanravan N. Effects of green coffee extract on fasting blood glucose, insulin concentration and homeostatic model assessment of insulin resistance (HOMA-IR): a systematic review and meta-analysis of interventional studies. *Diabetol Metab Syndr*. 2019;11:91. doi: [10.1186/s13098-019-0489-8](https://doi.org/10.1186/s13098-019-0489-8).
 44. Bontekoe E, Brailovsky Y, Hoppensteadt D, Bontekoe J, Siddiqui F, Newman J, et al. Upregulation of inflammatory cytokines in pulmonary embolism using biochip-array profiling. *Clin Appl Thromb Hemost*. 2021;27:10760296211013107. doi: [10.1177/10760296211013107](https://doi.org/10.1177/10760296211013107).